These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 38812772)

  • 21. Alter circulating cell-free DNA variables in plasma of ovarian cancer patients.
    Yu Z; Qin S; Wang H
    J Obstet Gynaecol Res; 2019 Nov; 45(11):2237-2242. PubMed ID: 31502389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High Sensitivity of Plasma Cell-Free DNA Genotyping in Cases With Evidence of Adequate Tumor Content.
    Meador CB; Milan MSD; Hu EY; Awad MM; Rabin MS; Paweletz CP; Hartmaier R; Laus G; Oxnard GR
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34250382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relationship between plasma cell-free DNA (cfDNA) and prognosis of TACE for primary hepatocellular carcinoma.
    Ma K; Liu J; Wang Y; Zhong Y; Wu Z; Fan R; Guo S
    J Gastrointest Oncol; 2020 Dec; 11(6):1350-1363. PubMed ID: 33457006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
    Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
    Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical significance of cell-free DNA concentration and integrity in serum of gastric cancer patients before and after surgery.
    Zhang X; Wu Z; Shen Q; Li R; Jiang X; Wu J; Li D; Wang D; Zou C; Zhong Y; Cheng X
    Cell Mol Biol (Noisy-le-grand); 2019 Sep; 65(7):111-117. PubMed ID: 31880527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The detection and significance of EGFR and BRAF in cell-free DNA of peripheral blood in NSCLC.
    Yang Y; Shen X; Li R; Shen J; Zhang H; Yu L; Liu B; Wang L
    Oncotarget; 2017 Jul; 8(30):49773-49782. PubMed ID: 28572536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of EGFR mutations in liquid biopsy samples using allele-specific quantitative PCR: A comparative real-world evaluation of two popular diagnostic systems.
    Szpechcinski A; Bryl M; Wojcik P; Czyzewicz G; Wojda E; Rudzinski P; Duk K; Moes-Sosnowska J; Maszkowska-Kopij K; Langfort R; Barinow-Wojewodzki A; Chorostowska-Wynimko J
    Adv Med Sci; 2021 Sep; 66(2):336-342. PubMed ID: 34274564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer.
    Markou AN; Londra D; Stergiopoulou D; Vamvakaris I; Potaris K; Pateras IS; Kotsakis A; Georgoulias V; Lianidou E
    Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980762
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative Analysis of Plasma Cell-Free DNA and Its DNA Integrity and Hypomethylation Status as Biomarkers for Tumor Burden and Disease Progression in Patients with Metastatic Neuroendocrine Neoplasias.
    Mettler E; Fottner C; Bakhshandeh N; Trenkler A; Kuchen R; Weber MM
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205773
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantification of mitochondrial cfDNA reveals new perspectives for early diagnosis of colorectal cancer.
    Linke C; Hunger R; Reinwald M; Deckert M; Mantke R
    BMC Cancer; 2023 Mar; 23(1):291. PubMed ID: 36997875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of serum cfDNA concentration and integrity before and after surgery in patients with lung cancer.
    Fan Y; Shi M; Chen S; Ju G; Chen L; Lu H; Chen J; Zheng S
    Cell Mol Biol (Noisy-le-grand); 2019 Jul; 65(6):56-63. PubMed ID: 31472048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis.
    Jiang T; Zhai C; Su C; Ren S; Zhou C
    Lung Cancer; 2016 Oct; 100():63-70. PubMed ID: 27597282
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating free DNA integrity index and promoter methylation of tumor suppressor gene P16, DAPK and RASSF1A as a biomarker for oropharyngeal squamous cell carcinoma.
    Kumari S; Mishra S; Anand N; Hadi R; Rastogi M; Husain N
    Pathol Res Pract; 2023 Jun; 246():154489. PubMed ID: 37150134
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of ubiquitous and heterogeneous mutations in cell-free DNA from patients with early-stage non-small-cell lung cancer.
    Jamal-Hanjani M; Wilson GA; Horswell S; Mitter R; Sakarya O; Constantin T; Salari R; Kirkizlar E; Sigurjonsson S; Pelham R; Kareht S; Zimmermann B; Swanton C
    Ann Oncol; 2016 May; 27(5):862-7. PubMed ID: 26823523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of Circulating Cell-Free DNA and Positron Emission Tomography to Distinguish Non-Small Cell Lung Cancer from Tuberculosis.
    Zheng W; Quan B; Gao G; Zhang P; Huang L
    Lab Med; 2023 Mar; 54(2):130-141. PubMed ID: 36106407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Diagnostic Value of Circulating Free DNA Integrity and Global Methylation Status in Gall Bladder Carcinoma.
    Kumari S; Husain N; Agarwal A; Neyaz A; Gupta S; Chaturvedi A; Lohani M; Sonkar AA
    Pathol Oncol Res; 2019 Jul; 25(3):925-936. PubMed ID: 29376201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Detection of cancer specific mutations in early-stage non-small cell lung cancer using cell-free DNA by targeted sequencing.
    He Y; Zhang X; Wang L; Tian Z; Liu Q; Yao J; Liu Y; Li C; Min L; Shan B
    Int J Oncol; 2016 Dec; 49(6):2351-2358. PubMed ID: 27748796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
    Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
    JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiparametric analysis of cell-free DNA in melanoma patients.
    Salvianti F; Pinzani P; Verderio P; Ciniselli CM; Massi D; De Giorgi V; Grazzini M; Pazzagli M; Orlando C
    PLoS One; 2012; 7(11):e49843. PubMed ID: 23209607
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.